KalVista Pharmaceuticals, Inc. (KALV) on Monday said that the U.S. Food and Drug Administration (FDA) has approved its drug ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Medicines and Healthcare products Regulatory Agency ...

Shares of KalVista Pharmaceuticals KALV have soared 36% in the past week, all thanks to the FDA’s approval of its lead pipeline drug for the hereditary angioedema (HAE) indication. Earlier this week, ...

Get the annual and quarterly balance sheet of KalVista Pharmaceuticals, Inc. (KALV) including details of assets, liabilities and shareholders' equity.

Review the current KalVista Pharmaceuticals Inc (KALV:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if KALV is the best investment for you.

Here are some of the largest recent moves: BOXER CAPITAL MANAGEMENT, LLC removed 1,590,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $18,348,600; SILVERARC CAPITAL ...

KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral treatment for a type of hereditary swelling disorder, sending its shares ...

KALV also recently performed a successful capital raise, providing it with enough resources for the foreseeable future until its potential commercialization begins in 2025.

KALV Stock Performance. Year to date, KalVista’s shares have surged 89% compared with the industry’s 5% growth. While commercial execution remains key, ...